Morgan Stanley Maintains Overweight on 2seventy bio, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $28 to $25.
July 20, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on 2seventy bio but lowers the price target from $28 to $25, which may impact the stock's performance.
The news is directly related to 2seventy bio (TSVT). While the Overweight rating is maintained, the lowering of the price target from $28 to $25 by Morgan Stanley might create a negative sentiment among investors, potentially impacting the stock's short-term performance. However, the overall impact is neutral as the Overweight rating indicates that Morgan Stanley still expects the stock to outperform.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100